Adagio Medical will present at the TD Cowen Healthcare Conference (Mar 3, 2026) on ULTA-based vCLAS cryoablation for ventricular tachycardia; FULCRUM-VT has enrolled 209 patients and aims for FDA PMA.Abstract: Adagio Medical announced a presentation at the TD Cowen 46th Annual Healthcare Conference on March 3, 2026, highlighting its ULTA-based vCLAS cryoablation system for ventricular tachycardia. The FULCRUM-VT trial has enrolled 209 patients and seeks FDA PMA for endocardial scar–mediated VT. The vCLAS system is CE-marked in Europe and is investigational in the United States.

SelfRugger

2026-05-14 23:35:02

Abstract generation in progress

This is a paid press release. Contact the press release distributor directly with any inquiries.

Adagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conference

Business Wire

Fri, February 20, 2026 at 10:00 PM GMT+9 2 min read

In this article:

ADGM

+0.82%

LAGUNA HILLS, Calif., February 20, 2026–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at 2:30 PM ET in Boston, MA.

**Presentation Information

**A live webcast and replay of the session will be accessible at or on the Company’s website at

About Adagio Medical Holdings, Inc.

Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cardiac (ULTA) ablation technology. ULTA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. Pivotal IDE Trial.

About FULCRUM VT

FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm trial, which has fully enrolled 209 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for FDA premarket approval (PMA) for Adagio’s vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT.

Adagio’s vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic VT in Europe and select other geographies but is limited to investigational use in the United States.

View source version on businesswire.com:

Contacts

Debbie Kaster
Chief Financial Officer and Chief Business Officer
dkaster@adagiomedical.com

Condiciones y Política de privacidad

Privacy Dashboard

More Info

IN0.33%

AT0.17%

PM2.12%

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.